menu close
Access The Private Market

Explore Companies

With a comprehensive suite of private market programming and liquidity solutions, Nasdaq Private Market can help unlock the power of data for market participants worldwide.

Asher Biotherapeutics

Develops targeted immunotherapies for cancer and diseases using a cis-targeting platform.

Attovia Therapeutics-Logo

Attovia

Pipeline of bio-therapeutics with an initial focus on immune-mediated diseases.

Attralus

Developing transformative medicines to improve the lives of patients with systemic amyloidosis.

Autobahn Therapeutics

Develops targeted therapeutics for neurological diseases using brain-targeting chemistry platform to create regenerative treatments for CNS disorders.

Avalyn Pharma

Develops inhaled therapies for rare respiratory diseases like idiopathic pulmonary fibrosis and interstitial lung diseases.

Avenzo Therapeutics

Advancing oncology with selective CDK inhibitors and bispecific ADCs to deliver precise, high-impact therapies for solid tumors.

Axial Therapeutics

Develops microbiome-based therapeutics targeting neurological disorders through gut-brain axis interventions using small molecule treatments.

Be Biopharma

Develops engineered B cell medicines and protein-based therapies to treat serious diseases, focusing on innovative therapeutic solutions.

Billiontoone-Logo

BillionToOne

Developed a DNA molecular counting technology for detecting gene disorders through a blood test.

Biomason

Develops sustainable biocement using biotechnology and natural processes to create eco-friendly concrete alternatives that reduce carbon emissions.

Biosplice

Developing small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing.

BostonGene

Advances personalized medicine and precision oncology by providing insights into the molecular profile of cancer.

BrainCo

Develops neurotechnology that enables cognitive enhancement and intuitive control through brain-computer interfaces.

CaaMTech

Pharmaceutical company develops novel psychedelic-inspired therapeutics targeting serotonin receptors to advance mental health treatments.

Cajal Neuroscience

Discovers drug targets for neurodegenerative diseases using advanced microscopy and genomics to develop treatments for brain disorders.

Cambrian Bio

Clinical-stage drug development company.

CAMP4

Specializes in programmable RNA-based therapeutics, which aim to provide targeted treatments for a variety of complex diseases.

Candid Therapeutics

Develops innovative therapies that utilize T-cell engager antibodies to selectively eliminate autoreactive B-cells, aiming to provide deeper and more durable therapeutic effects for autoimmune diseases.